Open-Label Extension Study of Omalizumab in Patients With Chronic Rhinosinusitis With Nasal Polyps
Phase of Trial: Phase III
Latest Information Update: 12 Feb 2019
At a glance
- Drugs Omalizumab (Primary)
- Indications Nasal polyps; Rhinosinusitis
- Focus Adverse reactions; Therapeutic Use
- Sponsors Roche
- 30 Nov 2018 Planned End Date changed from 5 May 2020 to 18 Mar 2020.
- 30 Nov 2018 Planned primary completion date changed from 5 May 2020 to 18 Mar 2020.
- 16 Apr 2018 Status changed from not yet recruiting to recruiting.